EUCTR2014-001429-33-PL进行中（未招募）1 期
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- > or equal to 18 years old, diagnosed with persistent or chronic ITP
- •- Patients must have received one or more ITP therapies and must have had initially responded to at least one prior ITP therapy
- •-Subjects have had relapsed ITP
- •-Platelet count must be less then 30,000/mm3 with no count greate than 35,000/mm3. If the mean of the counts is between 30,000-35,000/mm3, the subject may still be eligible but enrollment will be on a case by case basis and require approval by the Study Director.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •- Secondary immune thrombocytopenia
- •- Drug induced thrombocytopenia
- •- History of MDS
- •- Subject exhibit an identifiable alternative cause of their thrombocytopenia.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate safety and efficacy in adult subjects with ITPMedDRA version: 19.0 Level: LLT Classification code 10036735 Term: Primary thrombocytopenia System Organ Class: 100000004851Immune ThrombocytopeniaEUCTR2014-001429-33-GBBristol-Myers Squibb International Corporation26
招募中
不适用
Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies positive for CD123acute myeloid leukemiaNL-OMON53976AvenCell Europe GmbH10
招募中
1 期
An Open Label, Adaptive Design Evaluation, Crossover Study of the Safety, Pharmacokinetics and Pharmacodynamics of Various RECCE®327 Intravenous Dose and Infusion Ratesife threatening infectious diseaseLife threatening infectious diseaseInfection - Other infectious diseasesUrinary Tract InfectionACTRN12623000448640Recce Pharmaceuticals Ltd16
进行中（未招募）
2 期
A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorderISRCTN31103960Clerkenwell Health70
进行中（未招募）
1 期
A study in children and young adults with weak immunity and influenza (flu) infection to understand how the study drug (Tamiflu) improves the recovery from influenza (flu).EUCTR2012-002633-11-ESF. Hoffmann-La Roche Ltd.21